The voice of Utah’s life sciences community

Medical Devices

Pharmaceuticals

Diagnostics / Laboratory

Biotechnology

BioUtah is the common voice and flag bearer for Utah’s life sciences industry, comprised of medical devices, pharmaceuticals, diagnostics, laboratories, research facilities, and biotechnology of all types. BioUtah connects industry with government, academia, capital markets, media, and service providers. Together we form an ecosystem that fosters collaboration, promotes innovation, and delivers technology that saves lives.

Icons made by Freepik from www.flaticon.com is licensed by CC 3.0 BY

BIO Business Solutions

Savings achieved through this program on lab supplies, equipment, shipping and much more, often exceed the annual cost membership in BioUtah.

Bill Tracker

With the Utah legislature in session, follow the bills BioUtah is tracking that affect the life sciences industry.

Featured New Member

Definium Therapeutics is forging a new era of psychiatry by applying precision to psychedelic medicine.

Utah Life Sciences by the Numbers

Kem C. Gardner Report Findings Nov. 2023

Utah is #3 in the nation for life sciences growth.

Life sciences is a $21.6 billion industry in Utah.

Source: Pace, L. and Brandley, A. (2023), Economic Impacts of Utah’s Life Sciences and Health Care Innovation Industry: Utah’s Life Sciences and Health Care Innovation Industry Creates Substantial Economic Impacts Across the State, Kem C. Gardner Policy Institute, University of Utah.

BioUtah News

August 13, 2026

Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program

The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer.

August 13, 2026

Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval

Survival benefit is concentrated in participants with NfL biomarker response.

August 13, 2026

CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer

In-vitro studies confirmed revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells.

August 13, 2026

Teledyne to Acquire Varex Imaging Corporation

Teledyne will acquire all of the outstanding common shares of Varex for $18.90 per share, payable in cash.

August 7, 2026

BYU and BioUtah Connect Utah’s Life Sciences Industry at Annual Networking Lunch

BioUtah and BYU’s College of Life Sciences hosted the annual BYU/BioUtah Networking Lunch on August 7 at BYU’s Life Sciences Building in Provo. Nearly 100 people attended out of more than 100 registrants, bringing together life sciences companies from across the state with BYU’s research and tech transfer community. The lunch is one piece of […]

August 6, 2026

Strategic Transactions Advocacy Track (STAT)

STAT delivers U.S. Government Advocacy for Foreign Investment & Concession Projects

August 6, 2026

London Stock Exchange: Biggest Changes to AIM Rules in Two Decades

For more than 30 years, AIM has been Europe’s most successful growth market.

August 6, 2026

Receptor.AI, Sethera Plan to Create Closed-Loop Discovery, Optimization Workflow for Difficult Therapeutic Targets

Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow.

More BioUtah News